Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

MicroOne / shutterstock.com

Rheumatology Drugs at a Glance, Part 2: Psoriasis

Mary Choy, PharmD, BCGP, FASHP  |  May 17, 2019

Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Filed under:ConditionsDrug Updates Tagged with:adalimumabapremilastbrodalumabCertolizumab Pegoletanerceptguselkumabguttate psoriasisinfliximabinverse psoriasisixekizumabPsoriatic Arthritispsoriatic erythrodermapustular psoriasisRheumatic Drugs at a Glancesecukinumabtildrakizumabustekinumabvulgar psoriasis

IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  May 14, 2019

In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:CanadaFDAmeloxicamnon-opioid pain shotPainplaque psoriasisrizankixumabU.S. Food and Drug Administration (FDA)

Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  April 15, 2019

Japan has approved risankizumab for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults…

Filed under:Biologics/DMARDsDrug Updates Tagged with:JapanPsoriasisPsoriatic Arthritisrisankizumab

Mirikizumab Promising for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  April 10, 2019

During a 16-week study, patients with plaque psoriasis taking mirikizumab experienced higher response rates and skin clearance compared with placebo…

Filed under:Biologics/DMARDsDrug Updates Tagged with:mirikizumabplaque psoriasisskin

For Psoriasis, Ustekinumab & TNF Inhibitors Show Similar Cardiac Safety

David Douglas  |  April 9, 2019

NEW YORK (Reuters Health)—In patients with psoriasis and psoriatic arthritis, the incidence of atrial fibrillation and major adverse cardiovascular events does not differ between treatment with ustekinumab and TNF inhibitors, according to a large observational study. “Given a high cardiovascular risk among patients with psoriasis and psoriatic arthritis,” Seoyoung C. Kim, MD, ScD, MSCE, told…

Filed under:Conditions Tagged with:cardiovascularcardiovascular eventPsoriasisPsoriatic ArthritisSafetyTNF inhibitorustekinumab

FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review

Michele B. Kaufman, PharmD, BCGP  |  December 3, 2018

The FDA has approved halobetasol propionate lotion as a topical treatment for plaque psoriasis…

Filed under:Drug Updates Tagged with:dermatitisdupilumabFDAhalobetasol propionate lotionplaque psoriasisU.S. Food and Drug Administration (FDA)

Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence

Michele B. Kaufman, PharmD, BCGP  |  October 22, 2018

According to new data, BMS-986165, an oral, selective tyrosine kinase 2 inhibitor, may be safe and effective for treating plaque psoriasis…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabadalimumab-adbmBMS-986165plaque psoriasisTYK2 inhibitortyrosine kinase 2 inhibitor

Piclidenoson in Trials for Psoriasis & RA; Plus Duzallo Approved in Europe

Michele B. Kaufman, PharmD, BCGP  |  September 18, 2018

New clinical trials are underway to determine the safety and efficacy of piclidenoson for patients with plaque psoriasis and rheumatoid arthritis…

Filed under:Drug Updates Tagged with:DuzalloEuropeInternationalpiclidenosonPsoriasisRheumatoid Arthritis (RA)

Dietary Recommendations for Psoriasis Patients

Lara C. Pullen, PhD  |  August 2, 2018

The National Psoriasis Foundation says weight loss and other dietary interventions may benefit psoriasis patients. New recommendations note the benefits of a gluten-free diet for patients who test positive for gluten sensitivity, but also found little evidence to support the use of fish oil supplements for psoriasis patients…

Filed under:Conditions Tagged with:Dietdietary supplementNational Psoriasis Foundation (NPF)Psoriasisrecommendations

FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  July 9, 2018

The FDA has approved a combination of amlodipine and celecoxib, which may lower serum creatinine, for treating osteoarthritis pain and hypertension…

Filed under:AnalgesicsDrug Updates Tagged with:ConsensiDuobriiFDA approvalhypertensionosteoarthritis (OA)PainPain ManagementU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences